Company Overview - Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies across various modalities for autoimmune diseases and cancer [3] - The company has built a diversified portfolio of clinical-stage assets aimed at inhibiting key disease drivers and harnessing the immune system [3] - Cullinan aims to create new standards of care by identifying optimal targets and developing transformative therapeutics [3] Upcoming Events - The management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL [1] - An in-person event for analysts and institutional investors is scheduled for June 1, 2025, at 6:30 p.m. CT, following the oral presentation of results from the pivotal Phase 2b REZILIENT1 trial [4] - Participation in the Jefferies 2025 Global Healthcare Conference will include a panel discussion on June 4, 2025, and a company presentation on June 5, 2025 [4] Investor Relations - Webcasts of the ASCO event and Jefferies Conference presentations will be available on the company's investor relations website [2] - Investors and analysts can register for the in-person event by contacting the Head of Investor Relations [4]
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference